Anticancer potential of metformin: focusing on gastrointestinal cancers Mohammad rafi KhezriHassan MalekinejadMorteza Ghasemnejad-Berenji Review Article 20 March 2021 Pages: 587 - 598
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies Katharine A. CollierHugo ValenciaAmir Mortazavi Original Article 25 January 2021 Pages: 599 - 611
A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours Sunit SarkarBen TranAnne Hamilton Original Article 26 January 2021 Pages: 613 - 620
Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors Reza KhosravanSteven G. DuBoisErjian Wang Original Article Open access 28 January 2021 Pages: 621 - 634
Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach Ling GaoYiu-Keung LauPaolo Abada Original Article Open access 02 February 2021 Pages: 635 - 645
Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway Xianglan YiLiping LouSheng Zhou Original Article 05 February 2021 Pages: 647 - 656
Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population Jatta SaarenheimoNesna WahidAndré B. P. van Kuilenburg Original Article 05 February 2021 Pages: 657 - 663
Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study) Keiichiro IshibashiToru AoyamaHideyuki Mishima Original Article Open access 08 February 2021 Pages: 665 - 672
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer Filipa LynceJames T. WilliamsBeth Overmoyer Original Article 14 February 2021 Pages: 673 - 679
Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine Duo LiuXuehua LiMei Dong Original Article 14 February 2021 Pages: 681 - 687
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer Chao LiLowell HartJessica A. Sorrentino Original Article Open access 17 February 2021 Pages: 689 - 700
Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis Yang LiuYongde CaoHaijiang Wang Original Article 21 February 2021 Pages: 701 - 710
Comparison of a thymine challenge test and endogenous uracil–dihydrouracil levels for assessment of fluoropyrimidine toxicity risk Kathryn E. BurnsOttiniel ChavaniNuala A. Helsby Short Communication 09 March 2021 Pages: 711 - 716
Detecting DPD deficiency: when perfect is the enemy of good Joseph CiccoliniGérard MilanoHenk-Jan Guchelaar Letter to the Editor 09 March 2021 Pages: 717 - 719
Retraction Note to: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR‑181 level Anjing GongNa GeHui Liang Retraction Note 26 October 2020 Pages: 721 - 721